Search results
Results from the WOW.Com Content Network
Polyestradiol phosphate/medroxyprogesterone acetate (PEP/MPA) is a combination of polyestradiol phosphate (PEP), an estrogen, and medroxyprogesterone acetate (MPA), a progestin, which was studied in the 1960s as a long-lasting combined injectable contraceptive for women but was never marketed.
Medroxyprogesterone acetate (Amen, Curretab, Cycrin, Provera) – 2.5 mg, 5 mg, 10 mg Megestrol acetate (Megace) – 20 mg, 40 mg – approved specifically for the treatment of breast and endometrial cancer [ 46 ] and for the treatment of anorexia , cachexia , and weight loss in patients with AIDS Tooltip acquired immunodeficiency syndrome [ 47 ]
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. [10] [4] It is used as a method of birth control and as a part of menopausal hormone therapy.
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
Template: Pharmacokinetics of ... Download as PDF; Printable version; In other projects Appearance. ... Medroxyprogesterone acetate: Pregnane: 10 mg ~100%: 24 hours ...
Doses of component hormones also vary among products, and some pills are monophasic (delivering the same dose of hormones each day) while others are multiphasic (doses vary each day). combined oral contraceptive pills can also be divided into two groups, those with progestins that possess androgen activity (norethisterone acetate, etynodiol ...
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...
Progestogens that have been studied for potential use as POICs but were never marketed as such include the progesterone derivatives algestone acetophenide (dihydroxyprogesterone acetophenide) (100 mg/month), chlormadinone acetate (250 mg/3 months), hydroxyprogesterone caproate (250–500 mg/month), gestonorone caproate (2.5–200 mg/1–2 ...